H.pilory infection. Helicobacter pylori [H. pylori] as the cause of diseases classified elsewhere
Conditions
Interventions
Intervention 1: Intervention group: Treatment regimen A for 14 days containing PPI: Esomeprazole 40 mg BID (Abidi Pharmaceutical Company) - Amoxicillin: 1000 mg TDS (Subhan Pharmaceutical Company) -
Sponsors
Shahre-kord University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Helicobacter pylori positive Patients with first attempt at Helicobacter pylori eradication Age over 18 years
Exclusion criteria
Exclusion criteria: previous treatment for Helicobacter pylori eradication pregnancy or breastfeeding previous treatment for eradication of Helicobacter pylori malignant neoplasms history of gastrectomy history of allergy or adverse reactions to the study drugs history of use of PPIs and Potassium-Competitive Acid Blockers in the 2 weeks prior to randomization hematological disease, central nervous system infection, infectious mononucleosis, glucose-galactose malabsorption, lactase deficiency, galactose intolerance, or torsades de pointes Concomitant use of drugs that may interact with the drugs in the present study Withdrawal of consent or failure to complete the final test follow-up Development of drug hypersensitivity or intolerable adverse effects
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The eradication rate of Helicobacter pylori, which is defined as a negative stool antigen test. Timepoint: The stool antigen test is performed at the beginning of the study (before the intervention as an inclusion criterion) and four weeks after the completion of treatment. Method of measurement: Stool Antigen Test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Adherence to treatment. Timepoint: Four weeks after the completion of treatment. Method of measurement: Direct questioning of the patient and writing on the checklist.;The clinical symptoms of patients (pain, bloating, appetite, heartburn) and the incidence of side effects during treatment as reported by the patients. Timepoint: After the completion of treatment. Method of measurement: Direct questioning of the patient and writing on the checklist. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAli Sanei Dehkordi
Shahre-kord University of Medical Sciences
Outcome results
None listed